first-pass effect

When you swallow a drug, the blood that absorbs it from the gut does not go straight to the rest of the body. It is funnelled first through the liver — the body's chemical customs checkpoint — via the portal vein. The liver (and the gut wall itself) may metabolize a chunk of the drug on this very first pass, before it ever reaches the heart and general circulation. That loss is the first-pass effect.

Mechanistically, drug absorbed across the intestinal mucosa enters the hepatic portal vein and must traverse the liver before joining systemic blood. Enzymes such as the cytochrome P450 family (and gut-wall CYP3A4) and conjugation systems can transform a large fraction into metabolites. The greater this presystemic metabolism, the lower the oral bioavailability — which is why some drugs that are fully absorbed still deliver only a small active fraction.

Formulators and clinicians work around heavy first-pass loss in several ways: choosing routes that bypass the portal system (sublingual, buccal, transdermal, rectal to a degree, or parenteral), giving much larger oral doses to compensate, or designing prodrugs. The effect can also vary between patients with differing liver enzyme activity, making first-pass an important source of variable response.